Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality

被引：0
|
作者：
Lee, Nayoung [1 ]
Kim, Minlee [1 ]
Lee, JongAh Joanne [1 ]
Kim, Soohwan [1 ]
Yang, Hahymn [1 ]
机构：
[1] Samsung Bioepis, Incheon, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2495
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab
    Ruiz-Arguello, M. B.
    Maguregui, A.
    Martinez, A.
    Nagore, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S324 - S324
  • [22] VALIDATION OF A THERAPEUTIC DRUG MONITORING TEST TO MEASURE THE ADALIMUMAB BIOSIMILAR SB5 IN COMPARISON WITH THE REFERENCE ADALIMUMAB
    Begona Ruiz-Arguello, M.
    Maguregui, Ainara
    Martinez, Antonio
    Nagore, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1662 - 1663
  • [23] Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects
    Shin, Donghoon
    Lee, Younju
    Jeong, Deokyoon
    Ellis-Pegler, Rod
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3799 - 3805
  • [24] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Sitek-Ziolkowska, Karina
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Zhdan, Vyacheslav
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [25] A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)
    So-shin Ahn
    Minkyung Lee
    Yumin Baek
    Sukho Lee
    Rheumatology and Therapy, 2022, 9 : 1157 - 1169
  • [26] A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)
    Ahn, So-shin
    Lee, Minkyung
    Baek, Yumin
    Lee, Sukho
    RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1157 - 1169
  • [27] Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
    Derikx, L.
    Dolby, H.
    Plevris, N.
    Lucaciu, L.
    Rees, C.
    Lyons, M.
    Siakavellas, S.
    Constantine-Cooke, N.
    Noble, C.
    O'Hare, C.
    Merchant, L.
    Arnott, I.
    Jones, G. R.
    Lees, C.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S353 - S354
  • [28] Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature
    Dongkuk Park
    Jihoon Yun
    Su-Jeong Hwang
    Su Jin Park
    Advances in Therapy, 2019, 36 : 442 - 450
  • [29] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
    Fleischmann, Roy M.
    Alten, Rieke
    Pileckyte, Margarita
    Lobello, Kasia
    Hua, Steven Y.
    Cronenberger, Carol
    Alvarez, Daniel
    Bock, Amy E.
    Sewell, K. Lea
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [30] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
    Roy M. Fleischmann
    Rieke Alten
    Margarita Pileckyte
    Kasia Lobello
    Steven Y. Hua
    Carol Cronenberger
    Daniel Alvarez
    Amy E. Bock
    K. Lea Sewell
    Arthritis Research & Therapy, 20
12345